Tema Obesity & Cardiometabolic ETF (HRTS)
- Previous Close
33.99 - Open
33.96 - Bid 31.62 x 100
- Ask 36.73 x 100
- Day's Range
33.96 - 34.44 - 52 Week Range
26.26 - 36.03 - Volume
35,285 - Avg. Volume
20,818 - Net Assets 82.55M
- NAV 33.98
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return 11.04%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.75%
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
Tema Global Limited
Fund Family
Health
Fund Category
82.55M
Net Assets
2023-11-20
Inception Date
Performance Overview: HRTS
View MoreTrailing returns as of 10/15/2024. Category is Health.
People Also Watch
Holdings: HRTS
View MoreTop 10 Holdings (43.92% of Total Assets)
Sector Weightings
Recent News: HRTS
View MoreResearch Reports: HRTS
View MoreDaily – Vickers Top Buyers & Sellers for 10/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/01/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Lowering target price to $63.00
GXO LOGISTICS INC has an Investment Rating of BUY; a target price of $63.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetEli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins, Leading to Valuation Increase
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
RatingPrice Target